

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1 (currently amended): An isolated antibody which binds to a polypeptide having at least ~~[[80%]]~~99% amino acid sequence identity to:

- (a) the amino acid sequence shown in Figure 8 (SEQ ID NO:8);
- (b) the amino acid sequence shown in Figure 8 (SEQ ID NO:8), lacking its associated signal peptide;
- ~~(c) an amino acid sequence of the extracellular domain of the polypeptide shown in Figure 8 (SEQ ID NO:8), with its associated signal peptide;~~
- ~~(d) an amino acid sequence of the extracellular domain of the polypeptide shown in Figure 8 (SEQ ID NO:8), lacking its associated signal peptide;~~
- ~~[[e]]~~ an amino acid sequence encoded by the nucleotide sequence shown in Figure 3 (SEQ ID NO:3);
- ~~[[f]]~~(d) an amino acid sequence encoded by the full-length coding sequence of the nucleotide sequence shown in Figure 3 (SEQ ID NO:3); or
- ~~[[g]]~~(e) an amino acid sequence encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209750.

2 (currently amended): The antibody of Claim 1 which binds to a polypeptide comprising:

- (a) the amino acid sequence shown in Figure 8 (SEQ ID NO:8);
- (b) the amino acid sequence shown in Figure 8 (SEQ ID NO:8), lacking its associated signal peptide;
- ~~(c) an amino acid sequence of the extracellular domain of the polypeptide shown in Figure 8 (SEQ ID NO:8), with its associated signal peptide;~~
- ~~(d) an amino acid sequence of the extracellular domain of the polypeptide shown in Figure 8 (SEQ ID NO:8), lacking its associated signal peptide;~~
- ~~[[e]]~~ an amino acid sequence encoded by the nucleotide sequence shown in Figure 3 (SEQ ID NO:3);
- ~~[[f]]~~(d) an amino acid sequence encoded by the full-length coding sequence of the nucleotide sequence shown in Figure 3 (SEQ ID NO:3); or
- ~~[[g]]~~(e) an amino acid sequence encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209750.

- 3 (original): The antibody of Claim 1 which is a monoclonal antibody.
- 4 (original): The antibody of Claim 1 which is an antibody fragment.
- 5 (original): The antibody of Claim 1 which is a chimeric or a humanized antibody.
- 6 (original): The antibody of Claim 1 which is conjugated to a growth inhibitory agent.
- 7 (original): The antibody of Claim 1 which is conjugated to a cytotoxic agent.
- 8 (original): The antibody of Claim 7, wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.
- 9 (original): The antibody of Claim 7, wherein the cytotoxic agent is a toxin.
- 10 (original): The antibody of Claim 9, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.
- 11 (original): The antibody of Claim 9, wherein the toxin is a maytansinoid.
- 12 (original): The antibody of Claim 1 which is produced in bacteria.
- 13 (original): The antibody of Claim 1 which is produced in CHO cells.
- 14 (canceled)
- 15 (original): The antibody of Claim 1 which is detectably labeled.